Adalimumab (& biosimilars - Imraldi, Amgevita & Hyrimoz)

RED:

NICE TA373: for treating juvenile idiopathic arthritis (JIA). NHSE commissioned. (Decision date - January 2016)
NICE TA375: for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Decision date - February 2016)
NICE TA383: for ankylosing spondylitis and non-radiographic axial spondyloarthritis. (Decision date - March 2016)
NICE TA392: for treating moderate to severe hidradenitis suppurativa. NHSE commissioned. (Decision date - July 2016)
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. NHSE commissioned. (Decision date - August 2017)
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis. NHSE commissioned. (Decision date - August 2017)
NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)

Adalimumab biosimilars include Imraldi, Hyrimoz & Amgevita.

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)